论文部分内容阅读
目的:探讨急性上呼吸道感染病人采用利巴韦林治疗的效果。方法:本次临床研究选取200例我院2012年1月至2013年12月之间收治的急性上呼吸道感染患者为观察对象,随机分为对照组和实验组,对照组接受基础对症治疗,实验组接受利巴韦林治疗,对比分析两组临床疗效。结果:实验组患者治疗总有效率和症状控制情况均明显优于对照组(P<0.05)。结论:本次医学研究结果证实,利巴韦林是一种有效且安全的急性上呼吸道感染治疗药物,具有推广应用价值。
Objective: To investigate the effect of ribavirin treatment in patients with acute upper respiratory tract infection. Methods: The clinical study of 200 cases of our hospital from January 2012 to December 2013 admitted to patients with acute upper respiratory tract infection were randomly divided into control group and experimental group, the control group received basic symptomatic treatment, experimental Group received ribavirin treatment, comparative analysis of two groups of clinical efficacy. Results: The total effective rate and symptom control of experimental group were significantly better than that of control group (P <0.05). Conclusion: The results of this medical study confirmed that ribavirin is an effective and safe therapeutic agent for acute upper respiratory tract infection, and has the value of popularization and application.